

NIDA Clinical Trials Network: New York Node

Jennifer McNeely, MPI (NYU) Edward Nunes, MPI (Columbia)



NYU Langone Health




Clinical Trials Network (CTN)




Provides an enterprise in which NIDA, treatment researchers, and community-based service providers work toward new treatment options in community-level clinical practice.

https://nida.nih.gov/organization/center-clinical-trials-network-cctn/clinical-trials-network-ctn





NIDA Clinical Trials Network



- Established in 1999
- Mission to improve addiction treatment nationally using science as the vehicle

https://nida.nih.gov/organization/center-clinical-trials-network-cctn/clinical-trials-network-ctn


CTN's research focus




https://nida.nih.gov/about-nida/organization/cctn/ctn/research-studies

- Over 150 funded studies
- Primarily rigorous multi-site clinical trials
- Testing new treatment models, behavioral therapies, and medications
- Improving the reach of evidence-based treatment across diverse treatment settings and participants
 - Community SUD treatment programs
 - Medical settings: primary care, ED, hospital
 - Evolving focus on minoritized and underserved populations, community-based work
- Provide a platform for related studies and training new investigators







CTN New York Node








- One of the first CTN nodes, est. 2000
- Based at NYU and Columbia
- NYU MPI John Rotrosen transitioned to Jennifer McNeely in July 2023
- Columbia MPIs Edward Nunes + Aimee Campbell
- Largest node in the network currently
- Lead node for 24+ trials



Organizational Chart 2025-2032





How does research happen in the CTN?

- Node provides basic infrastructure
- Individual studies funded through supplements
- The Node may lead or participate in studies
- Node works with investigators to develop and submit study concepts
- Concepts are reviewed by CTN Research
 Development Committee (monthly meeting)
- Funding decisions are based on CTN/NIDA priorities



Current studies in the CTN NY Node

- CTN-0096: Culturally Centering the Delivery of Medications for Opioid Disorder with AI/AN Communities (Tribal MOUD) – Venner, Campbell
- CTN-0100: Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) - Nunes, Weiss, Rotrosen



- CTN-0101: Subthreshold OUD Prevention Trial (STOP) McNeely & Liebschutz
- CTN-0112: Optimal Policies to Improve Methadone Maintenance Adherence Long-Term (OPTIMMAL) – Williams & Krawczyk
- CTN-0125: Integrative Data Analysis of CTN Studies to Examine the Impact of Psychosocial Treatments for Black People who use Cocaine – Burlew & Ruglass
- CTN-0126: Longitudinal Follow-up of Individuals with OUD Hefner, McHugh, Shulman
- CTN-0139: Collaborative Care for Polysubstance Use in Primary Care Settings (Co-Care) – McNeely & Liebschutz



CTN Special Interest Groups (SIGs)

- American Indian/Alaska Native (AIAN) SIG
- Comorbidities SIG
- Gender SIG
- Minority Interest Group (MIG)
- Primary Care SIG
- Rural SIG
- Telehealth & Telemedicine SIG
- Translation and Implementation SIG
- Youth SIG



Aims of next grant cycle (2025-2032)

- 1. Broaden the reach of SUD services to diverse populations, through low-barrier and community-based treatment models
- 2. Integrate evidence-based addiction treatment in healthcare settings
- 3. Increase SUD treatment effectiveness by addressing mental health comorbidities and polysubstance use
- 4. Investigate novel treatments, including medications and digital therapeutics
- 5. Use existing data to study interventions in real-world care settings and inform new research questions
- 6. Train the next generation of addiction researchers





Thank you

Supporting text and contact information

